Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience

BACKGROUND: The mortality caused by hepatocellular carcinoma is expected to rise in the upcoming decade. Sorafenib has become the preferred systemic treatment option in patients with unresectable HCC. This study aimed to present the median overall survival (OS) in a group of patients with advanced H...

Descripción completa

Detalles Bibliográficos
Autores principales: Straś, Wojciech, Gotlib, Joanna, Małkowski, Piotr, Wasiak, Dariusz, Śliwczyński, Andrzej, Panczyk, Mariusz, Tronina, Olga, Brzozowska, Melania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418957/
https://www.ncbi.nlm.nih.gov/pubmed/34462415
http://dx.doi.org/10.12659/MSM.931856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418957/
https://www.ncbi.nlm.nih.gov/pubmed/34462415
http://dx.doi.org/10.12659/MSM.931856

Ejemplares similares